One Trial, 57 Sites: What October 2026 Shows About Clinical Trials in India

The October 2026 edition of IndiaTrialPulse is now live. One October trial alone spans 57 Indian sites in 36 cities.

Every month, IndiaTrialPulse tracks multi-site clinical trial activity registered with the Clinical Trials Registry of India (CTRI). In October, 562 clinical trials were registered. Of these, 50 were multi-site trials, running across 416 sites in 75 cities.

This blog covers trials registered under Drug, Biological, Vaccine, Stem Cell Therapy, Ayurveda, and Medical Device. This blog gives you a glimpse of the data and what it means for digital clinical trials in India.

Therapeutic Areas

In terms of therapeutic areas, Metabolic & Endocrinology led the month with 11 trials. Oncology followed with 8, then CNS/Neurology with 6, Gastroenterology with 5, Cardiology with 4, and Infectious Disease & Vaccines with 3.

Sponsors

Global Pharma sponsored 20 of the 50 multi-site trials, or 40%. Indian Pharma was close behind with 18 trials (36%). Other sponsors accounted for 7 trials (14%), and government institutions for 5 (10%).

Where the sites are

North India held 140 of the 416 trial sites, or 34%. South India had 118 sites (28%), and West India had 110 (26%).

East and Central India tell a different story. East India had 41 sites (10%), and Central India had just 7 (2%). Together, they held only 12% of all sites this month.

At the city level, Delhi led with 47 sites, followed by Mumbai with 25 and Hyderabad with 24.

Study phase

Phase 3 was the largest group, with 20 trials. Add the 7 Phase 4 trials, and 54% of October’s multi-site trials were in Phase 3 or Phase 4.

Trial of the month

The largest trial this month is a Phase 3 cardiology study sponsored by Global Pharma (CTRI/2026/10/120233). It looks at how well zenagamtide works compared to placebo in people with established atherosclerotic cardiovascular disease and either overweight or obesity.

The study spans 57 sites in 36 cities. By region, North India has 20 of these sites, West 17, South 14, East 4, and Central 2.

Even this trial follows the month’s wider pattern. Only 6 of its 57 sites are in East and Central India.

Why this matters for digital clinical trials in India

Large parts of India are still far from a trial site. In October, East and Central India together had 48 of 416 multi-site trial sites. For many patients in these regions, the nearest study site can be a long way from home.

Digital clinical trials can help fill that gap. Tools like eConsent and ePRO, along with StriderDCT’s Mobile Research Nursing Network, allow parts of a study to happen closer to where patients live. As multi-site trials in India grow in size, this is one way to reach patients beyond the cities where most sites are today.

About StriderDCT

StriderDCT is an AI-native, full-spectrum clinical research organization advancing Digital Clinical Trials across India and beyond.

From BA/BE and conventional studies to decentralized and hybrid delivery, we help sponsors and CROs run trials with less burden on sites and patients and turn clinical data into the kind of intelligence teams can act on.

Follow StriderDCT for the next edition of IndiaTrialPulse.